Survivin overexpression in head and neck squamous cell carcinomas as a new therapeutic target (Review)
- Authors:
- M. A. Frassanito
- I. Saltarella
- A. Vinella
- L. Lo Muzio
- G. Pannone
- R. Fumarulo
- A. Vacca
- M. A. Mariggiò
-
Affiliations: Department of Biomedical Sciences and Human Oncology, Unit of General Pathology, University of Bari Aldo Moro, I‑70124 Bari, Italy, Department of Biomedical Sciences and Human Oncology, Unit of Internal Medicine and Clinical Oncology, University of Bari Aldo Moro, I‑70124 Bari, Italy, Department of Clinical and Experimental Medicine, University of Foggia, I‑70121 Foggia, Italy - Published online on: March 21, 2019 https://doi.org/10.3892/or.2019.7082
- Pages: 2615-2624
This article is mentioned in:
Abstract
 |
 |
|
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bose P, Brockton NT and Dort JC: Head and neck cancer: From anatomy to biology. Int J Cancer. 133:2013–2023. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Rothenberg SM and Ellisen LW: The molecular pathogenesis of head and neck squamous cell carcinoma. J Clin Invest. 122:1951–1957. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Leemans CR, Braakhuis BJ and Brakenhoff RH: The molecular biology of head and neck cancer. Nat Rev Cancer. 11:9–22. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Fakhry C and Gillison ML: Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol. 24:2606–2611. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Wang C, Liu XQ, Hou JS, Wang JN and Huang HZ: Molecular mechanisms of chemoresistance in oral cancer. Chin J Dent Res. 19:25–33. 2016.PubMed/NCBI | |
|
Brown JM and Attardi LD: The role of apoptosis in cancer development and treatment response. Nat Rev Cancer. 5:231–237. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Mohammad RM, Muqbil I, Lowe L, Yedjou C, Hsu HY, Lin LT, Siegelin MD, Fimognari C, Kumar NB, Dou QP, et al: Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol. 35 (Suppl):S78–S103. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Mita AC, Mita MM, Nawrocki ST and Giles FJ: Survivin: Key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 14:5000–5005. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Desantis V, Saltarella I, Lamanuzzi A, Mariggiò MA, Racanelli V, Vacca A and Frassanito MA: Autophagy: A new mechanism of prosurvival and drug resistance in multiple myeloma. Transl Oncol. 11:1350–1357. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yang ZJ, Chee CE, Huang S and Sinicrope FA: Autophagy modulation for cancer therapy. Cancer Biol Ther. 11:169–176. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Sannigrahi MK, Singh V, Sharma R, Panda NK and Khullar M: Role of autophagy in head and neck cancer and therapeutic resistance. Oral Dis. 21:283–291. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mizushima N: Autophagy: Process and function. Genes Dev. 21:2861–2873. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Altieri DC: Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 22:8581–8589. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Jaiswal PK, Goel A and Mittal RD: Survivin: A molecular biomarker in cancer. Indian J Med Res. 141:389–397. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Verdecia MA, Huang H, Dutil E, Kaiser DA, Hunter T and Noel JP: Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol. 7:602–608. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Chantalat L, Skoufias DA, Kleman JP, Jung B, Dideberg O and Margolis RL: Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions. Mol Cell. 6:183–189. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Caldas H, Honsey LE and Altura RA: Survivin 2alpha: A novel Survivin splice variant expressed in human malignancies. Mol Cancer. 4:112005. View Article : Google Scholar : PubMed/NCBI | |
|
Mahotka C, Wenzel M, Springer E, Gabbert HE and Gerharz CD: Survivin-deltaEx3 and survivin-2B: Two novel splice variants of The apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 59:6097–6102. 1999.PubMed/NCBI | |
|
Mahotka C, Liebmann J, Wenzel M, Suschek CV, Schmitt M, Gabbert HE and Gerharz CD: Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ. 9:1334–1342. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
De Maria S, Pannone G, Bufo P, Santoro A, Serpico R, Metafora S, Rubini C, Pasquali D, Papagerakis SM, Staibano S, et al: Survivin gene-expression and splicing isoforms in oral squamous cell carcinoma. J Cancer Res Clin Oncol. 135:107–116. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Fortugno P, Wall NR, Giodini A, O'Connor DS, Plescia J, Padgett KM, Tognin S, Marchisio PC and Altieri DC: Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci. 115:575–585. 2002.PubMed/NCBI | |
|
Altieri DC: New wirings in the survivin networks. Oncogene. 27:6276–6284. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Cheung CH, Huang CC, Tsai FY, Lee JY, Cheng SM, Chang YC, Huang YC, Chen SH and Chang JY: Survivin-biology and potential as a therapeutic target in oncology. Onco Targets Ther. 6:1453–1462. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Vaira V, Lee CW, Goel HL, Bosari S, Languino LR and Altieri DC: Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene. 26:2678–2684. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Aoki Y, Feldman GM and Tosato G: Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood. 101:1535–1542. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Kanda N, Seno H, Konda Y, Marusawa H, Kanai M, Nakajima T, Kawashima T, Nanakin A, Sawabu T, Uenoyama Y, et al: STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene. 23:4921–4929. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, et al: Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res. 12:11–9. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Li W, Cao Y, Xu J, Wang Y, Li W, Wang Q, Hu Z, Hao Y, Hu L, Sun Y, et al: YAP transcriptionally regulates COX-2 expression and GCCSysm-4 (G-4), a dual YAP/COX-2 inhibitor, overcomes drug resistance in colorectal cancer. J Exp Clin Cancer Res. 36:1442017. View Article : Google Scholar : PubMed/NCBI | |
|
Barrett RM, Osborne TP and Wheatley SP: Phosphorylation of survivin at threonine 34 inhibits its mitotic function and enhances its cytoprotective activity. Cell Cycle. 8:278–283. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Duckett CS, Nava VE, Gedrich RW, Clem RJ, Van Dongen JL, Gilfillan MC, Shiels H, Hardwick JM and Thompson CB: A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. EMBO J. 15:2685–2694. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Deveraux QL, Takahashi R, Salvesen GS and Reed JC: X-linked IAP is a direct inhibitor of cell-death proteases. Nature. 388:300–304. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
LaCasse EC, Baird S, Korneluk RG and MacKenzie AE: The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 17:3247–3259. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, Tognin S, Villa A, Marchisio PC and Altieri DC: Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol. 1:461–426. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Altieri DC: Targeting survivin in cancer. Cancer Lett. 332:225–228. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T and Reed JC: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58:5315–5320. 1998.PubMed/NCBI | |
|
Croci DO, Cogno IS, Vittar NB, Salvatierra E, Trajtenberg F, Podhajcer OL, Osinaga E, Rabinovich GA and Rivarola VA: Silencing survivin gene expression promotes apoptosis of human breast cancer cells through a caspase-independent pathway. J Cell Biochem. 105:381–390. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Ceballos-Cancino G, Espinosa M, Maldonado V and Melendez-Zajgla J: Regulation of mitochondrial Smac/DIABLO-selective release by survivin. Oncogene. 26:7569–7575. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Du C, Fang M, Li Y, Li L and Wang X: Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 102:33–42. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Song Z, Yao X and Wu M: Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem. 278:23130–23140. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Ghosh JC, Dohi T, Kang BH and Altieri DC: Hsp60 regulation of tumor cell apoptosis. J Biol Chem. 283:5188–5194. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Fortugno P, Beltrami E, Plescia J, Fontana J, Pradhan D, Marchisio PC, Sessa WC and Altieri DC: Regulation of survivin function by Hsp90. Proc Natl Acad Sci USA. 100:13791–13796. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Marx J: Autophagy: Is it cancer's friend or foe. Science. 312:1160–1161. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Galluzzi L, Vicencio JM, Kepp O, Tasdemir E, Maiuri MC and Kroemer G: To die or not to die: That is the autophagic question. Curr Mol Med. 8:78–91. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Decuypere JP, Parys JB and Bultynck G: Regulation of the autophagic bcl-2/Beclin 1 interaction. Cells. 1:284–312. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bhutia SK, Dash R, Das SK, Azab B, Su ZZ, Lee SG, Grant S, Yacoub A, Dent P, Curiel DT, et al: Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24. Cancer Res. 70:3667–3676. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Haller M, Hock AK, Giampazolias E, Oberst A, Green DR, Debnath J, Ryan KM, Vousden KH and Tait SW: Ubiquitination and proteasomal degradation of ATG12 regulates its proapoptotic activity. Autophagy. 10:2269–2278. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Norman JM, Cohen GM and Bampton ET: The in vitro cleavage of the hAtg proteins by cell death proteases. Autophagy. 6:1042–1056. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wu H, Che X, Zheng Q, Wu A, Pan K, Shao A, Wu Q, Zhang J and Hong Y: Caspases: A molecular switch node in the crosstalk between autophagy and apoptosis. Int J Biol Sci. 10:1072–1083. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Han J, Hou W, Goldstein LA, Stolz DB, Watkins SC and Rabinowich H: A Complex between Atg7 and Caspase-9: A novel mechanism of cross-regulation between autophagy and apoptosis. J Biol Chem. 289:6485–6497. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Coumar MS, Tsai FY, Kanwar JR, Sarvagalla S and Cheung CH: Treat cancers by targeting survivin: Just a dream or future reality. Cancer Treat Rev. 39:802–811. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Niu TK, Cheng Y, Ren X and Yang JM: Interaction of Beclin 1 with survivin regulates sensitivity of human glioma cells to TRAIL-induced apoptosis. FEBS Lett. 584:3519–3524. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Roca H, Varsos ZS, Mizutani K and Pienta KJ: CCL2, survivin and autophagy: New links with implications in human cancer. Autophagy. 4:969–971. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Loberg RD, Day LL, Harwood J, Ying C, St John LN, Giles R, Neeley CK and Pienta KJ: CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia. 8:578–586. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Minematsu T, Iwai M, Sugimoto K, Shirai N, Nakahara T, Usui T and Kamimura H: Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells. Drug Metab Dispos. 37:619–628. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng SM, Chang YC, Liu CY, Lee JY, Chan HH, Kuo CW, Lin KY, Tsai SL, Chen SH, Li CF, et al: YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells. Br J Pharmacol. 172:214–234. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Khan Z, Khan AA, Yadav H, Prasad GBKS and Bisen PS: Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma. Cell Mol Biol Lett. 22:82017. View Article : Google Scholar : PubMed/NCBI | |
|
Rong L, Hongyan Guo H and Liu K: The role of survivin in oral squamous cell carcinoma. Biom Res. 29:780–783. 2018. | |
|
Lo Muzio L, Pannone G, Leonardi R, Staibano S, Mignogna MD, De Rosa G, Kudo Y, Takata T and Altieri DC: Survivin, a potential early predictor of tumor progression in the oral mucosa. J Dent Res. 82:923–928. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Lo Muzio L, Pannone G, Staibano S, Mignogna MD, Rubini C, Mariggiò MA, Procaccini M, Ferrari F, De Rosa G and Altieri DC: Survivin expression in oral squamous cell carcinoma. Br J Cancer. 89:2244–2248. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Lo Muzio L, Farina A, Rubini C, Pezzetti F, Stabellini G, Laino G, Santarelli A, Pannone G, Bufo P, de Lillo A and Carinci F: Survivin as prognostic factor in squamous cell carcinoma of the oral cavity. Cancer Lett. 225:27–33. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Lo Muzio L, Staibano S, Pannone G, Mignogna MD, Mariggiò A, Salvatore G, Chieffi P, Tramontano D, De Rosa G and Altieri DC: Expression of the apoptosis inhibitor survivin in aggressive squamous cell carcinoma. Exp Mol Pathol. 70:249–254. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Su L, Wang Y, Xiao M, Lin Y and Yu L: Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 110:484–491. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kim MJ, Lim KY, Kim JW, Nam IW, Lee JH and Myoung H: Stage and mRNA expression of survivin in lymph node as prognostic indicators in patients with oral squamous cell carcinoma. Cancer Lett. 224:253–261. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang M, Li J, Wang L, Tian Z, Zhang P, Xu Q, Zhang C, Wei F and Chen W: Prognostic significance of p21, p27 and survivin protein expression in patients with oral squamous cell carcinoma. Oncol Lett. 6:381–386. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Münscher A, Prochnow S, Gulati A, Sauter G, Lörincz B, Blessmann M, Hanken H, Böttcher A and Clauditz TS: Survivin expression in head and neck squamous cell carcinomas is frequent and correlates with clinical parameters and treatment outcomes. Clin Oral Investig. 23:361–367. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Xie S, Xu H, Shan X, Liu B, Wang K and Cai Z: Clinicopathological and prognostic significance of survivin expression in patients with oral squamous cell carcinoma: Evidence from a meta-analysis. PLoS One. 10:e01165172015. View Article : Google Scholar : PubMed/NCBI | |
|
Engels K, Knauer SK, Metzler D, Simf C, Struschka O, Bier C, Mann W, Kovács AF and Stauber RH: Dynamic intracellular survivin in oral squamous cell carcinoma: Underlying molecular mechanism and potential as an early prognostic marker. J Pathol. 211:532–540. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Liu S, Shi L, Yang X, Ye D, Wang T, Dong C, Guo W, Liao Y, Song H, Xu D, et al: Nuclear survivin promoted by acetylation is associated with the aggressive phenotype of oral squamous cell carcinoma. Cell Cycle. 16:894–902. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Troiano G, Guida A, Aquino G, Botti G, Losito NS, Papagerakis S, Pedicillo MC, Ionna F, Longo F, Cantile M, et al: Integrative histologic and bioinformatics analysis of BIRC5/Survivin expression in oral squamous cell carcinoma. Int J Mol Sci. 19(pii): E26642018. View Article : Google Scholar : PubMed/NCBI | |
|
Aguilera P, Malvehy J, Carrera C, Palou J, Puig-Butillé JA, Alòs L, Badenas C and Puig S: Clinical and histopathological characteristics between familial and sporadic melanoma in Barcelona, Spain. J Clin Exp Dermatol Res. 5:2312014.PubMed/NCBI | |
|
Lyu H, Huang J, He Z and Liu B: Epigenetic mechanism of survivin dysregulation in human cancer. Sci China Life Sci. 61:808–814. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chen YK, Hsue SS and Lin LM: Survivin expression is regulated by an epigenetic mechanism for DMBA-induced hamster buccal-pouch squamous-cell carcinomas. Arch Oral Biol. 50:593–598. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Hsue SS, Wang WC, Chen YK and Lin LM: Expression of inhibitors of apoptosis family protein in 7,12-dimethylbenz[a]anthracene-induced hamster buccal-pouch squamous-cell carcinogenesis is associated with mutant p53 accumulation and epigenetic changes. Int J Exp Pathol. 89:309–320. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Tanaka C, Uzawa K, Shibahara T, Yokoe H, Noma H and Tanzawa H: Expression of an inhibitor of apoptosis, survivin, in oral carcinogenesis. J Dent Res. 82:607–611. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Khan Z, Tiwari RP, Mulherkar R, Sah NK, Prasad GB, Shrivastava BR and Bisen PS: Detection of survivin and p53 in human oral cancer: Correlation with clinicopathologic findings. Head Neck. 31:1039–1048. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ikuta M, Podyma KA, Maruyama K, Enomoto S and Yanagishita M: Expression of heparanase in oral cancer cell lines and oral cancer tissues. Oral Oncol. 37:177–184. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Michi Y, Morita I, Amagasa T and Murota S: Human oral squamous cell carcinoma cell lines promote angiogenesis via expression of vascular endothelial growth factor and upregulation of KDR/flk-1 expression in endothelial cells. Oral Oncol. 36:81–88. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Gioanni J, Fischel JL, Lambert JC, Demard F, Mazeau C, Zanghellini E, Ettore F, Formento P, Chauvel P, Lalanne CM and Courdi A: Two new human tumor cell lines derived from squamous cell carcinomas of the tongue: Establishment, characterization and response to cytotoxic treatment. Eur J Cancer Clin Oncol. 24:1445–1455. 1988. View Article : Google Scholar : PubMed/NCBI | |
|
de Maria S, Lo Muzio L, Braca A, Rega P, Cassano A, Vinella A, Fumarulo R, Serpico R, Farina E, Metafora V, et al: Survivin promoter-31G/C polymorphism in oral cancer cell lines. Oncol Lett. 2:935–939. 2011.PubMed/NCBI | |
|
Chou J, Lin YC, Kim J, You L, Xu Z, He B and Jablons DM: Nasopharyngeal carcinoma-review of the molecular mechanisms of tumorigenesis. Head Neck. 30:946–963. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Altieri DC: Survivin-The inconvenient IAP. Semin Cell Dev Biol. 39:91–96. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Altieri DC: Survivin and IAP proteins in cell-death mechanisms. Biochem J. 430:199–205. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Duan N, Zhang C and Zhang W: Survivin and tumorigenesis: Molecular mechanisms and therapeutic strategies. J Cancer. 7:314–323. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kanwar JR, Kamalapuram SK and Kanwar RK: Targeting survivin in cancer: The cell-signalling perspective. Drug Discov Today. 16:485–494. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Beitler JJ, Huang W, Chen G, Qian G, Magliocca K, Patel MR, Chen AY, Zhang J, Nannapaneni S, et al: Honokiol Radiosensitizes squamous cell carcinoma of the head and neck by downregulation of survivin. Clin Cancer Res. 24:858–869. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hu J, Pan J, Luo Z and Tao Z: Downregulation of survivin by shRNA inhibits invasion and enhances the radiosensitivity of laryngeal squamous cell carcinoma. Cell Biochem Biophys. 72:251–257. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Santarelli A, Mascitti M, Lo Russo L, Sartini D, Troiano G, Emanuelli M and Lo Muzio L: Survivin-based treatment strategies for squamous cell carcinoma. Int J Mol Sci. 19(pii): E9712018. View Article : Google Scholar : PubMed/NCBI | |
|
Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Kinoyama I, Matsuhisa A, Kudou M and Sasamata M: Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci. 102:614–621. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yan X and Su H: YM155 Down-regulates survivin and induces P53 Up-regulated modulator of apoptosis (PUMA)-dependent in oral squamous cell carcinoma cells. Med Sci Monit. 23:1963–1972. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Zhang W, Wang YF, Liu B, Zhang WF, Zhao YF, Kulkarni AB and Sun ZJ: Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma. Cell Death Dis. 6:e17712015. View Article : Google Scholar : PubMed/NCBI | |
|
Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P, et al: Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol. 26:5198–5203. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Satoh T, Okamoto I, Miyazaki M, Morinaga R, Tsuya A, Hasegawa Y, Terashima M, Ueda S, Fukuoka M, Ariyoshi Y, et al: Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res. 15:3872–3880. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, Kuta M, van Klaveren RJ, Chaudhary S, Gunther A and Shamsili S: Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol. 27:4481–4486. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kelly RJ, Thomas A, Rajan A, Chun G, Lopez-Chavez A, Szabo E, Spencer S, Carter CA, Guha U, Khozin S, et al: A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Ann Oncol. 24:2601–2606. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Gurpinar E, Grizzle WE and Piazza GA: NSAIDs inhibit tumorigenesis, but how? Clin Cancer Res. 20:1104–1113. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tinsley HN, Grizzle WE, Abadi A, Keeton A, Zhu B, Xi Y and Piazza GA: New NSAID targets and derivatives for colorectal cancer chemoprevention. Recent Results Cancer Res. 191:105–120. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Sato A, Mizobuchi Y, Nakajima K, Shono K, Fujihara T, Kageji T, Kitazato K, Matsuzaki K, Mure H, Kuwayama K, et al: Blocking COX-2 induces apoptosis and inhibits cell proliferation via the Akt/survivin- and Akt/ID3 pathway in low-grade-glioma. J Neurooncol. 132:231–238. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Scheper MA, Nikitakis NG, Chaisuparat R, Montaner S and Sauk JJ: Sulindac induces apoptosis and inhibits tumor growth in vivo in head and neck squamous cell carcinoma. Neoplasia. 9:192–199. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Chiou SK and Mandayam S: NSAIDs enhance proteasomic degradation of survivin, a mechanism of gastric epithelial cell injury and apoptosis. Biochem Pharmacol. 74:1485–1495. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Chiou SK, Hoa N, Hodges A, Ge L and Jadus MR: Indomethacin promotes apoptosis in gastric cancer cells through concomitant degradation of Survivin and Aurora B kinase proteins. Apoptosis. 19:1378–1388. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Olie RA, Simões-Wüst AP, Baumann B, Leech SH, Fabbro D, Stahel RA and Zangemeister-Wittke U: A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 60:2805–2809. 2000.PubMed/NCBI | |
|
Talbot DC, Ranson M, Davies J, Lahn M, Callies S, André V, Kadam S, Burgess M, Slapak C, Olsen AL, et al: Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: A proof-of-concept, first-in-human dose study. Clin Cancer Res. 16:6150–6158. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Hansen JB, Fisker N, Westergaard M, Kjaerulff LS, Hansen HF, Thrue CA, Rosenbohm C, Wissenbach M, Orum H and Koch T: SPC3042: A proapoptotic survivin inhibitor. Mol Cancer Ther. 7:2736–2745. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Sapra P, Wang M, Bandaru R, Zhao H, Greenberger LM and Horak ID: Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide. Nucleosides Nucleotides Nucleic Acids. 29:97–112. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Carrasco RA, Stamm NB, Marcusson E, Sandusky G, Iversen P and Patel BK: Antisense inhibition of survivin expression as a cancer therapeutic. Mol Cancer Ther. 10:221–232. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kojima H, Iida M, Yaguchi Y, Suzuki R, Hayashi N, Moriyama H and Manome Y: Enhancement of Cisplatin sensitivity in squamous cell carcinoma of the head and neck transfected with a survivin antisense gene. Arch Otolaryngol Head Neck Surg. 132:682–685. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Tanioka M, Nokihara H, Yamamoto N, Yamada Y, Yamada K, Goto Y, Fujimoto T, Sekiguchi R and Uenaka K: Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 68:505–511. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Schmidt SM, Schag K, Müller MR, Weck MM, Appel S, Kanz L, Grünebach F and Brossart P: Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood. 102:571–576. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Schmitz M, Diestelkoetter P, Weigle B, Schmachtenberg F, Stevanovic S, Ockert D, Rammensee HG and Rieber EP: Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res. 60:4845–4849. 2000.PubMed/NCBI | |
|
Miyazaki A, Kobayashi J, Torigoe T, Hirohashi Y, Yamamoto T, Yamaguchi A, Asanuma H, Takahashi A, Michifuri Y, Nakamori K, et al: Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer. Cancer Sci. 102:324–329. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hirohashi Y, Torigoe T, Maeda A, Nabeta Y, Kamiguchi K, Sato T, Yoda J, Ikeda H, Hirata K, Yamanaka N and Sato N: An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res. 8:1731–1739. 2002.PubMed/NCBI | |
|
Idenoue S, Hirohashi Y, Torigoe T, Sato Y, Tamura Y, Hariu H, Yamamoto M, Kurotaki T, Tsuruma T, Asanuma H, et al: A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin Cancer Res. 11:1474–1482. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Z, Wang T, Zhang Z, Tang S, Feng S, Yue M, Hu M, Xuan L and Chen Y: Survivin downregulation using siRNA nanoliposomes inhibits cell proliferation and promotes the apoptosis of MHCC-97H hepatic cancer cells: An in vitro and in vivo study. Oncol Lett. 13:2723–2730. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Z, Wang T, Liu Z, Tang S, Yue M, Feng S, Hu M, Xuan L and Chen Y: Small interfering RNA targeting of the survivin gene inhibits human tumor cell growth in vitro. Exp Ther Med. 14:35–42. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Liu D, Zhou Y, Li Y, Xie J, Lee RJ, Cai Y and Teng L: Silencing of survivin expression leads to reduced proliferation and cell cycle arrest in cancer cells. J Cancer. 6:1187–1194. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Xu JH, Wang AX, Huang HZ, Wang JG, Pan CB and Zhang B: Survivin shRNA induces caspase-3-dependent apoptosis and enhances cisplatin sensitivity in squamous cell carcinoma of the tongue. Oncol Res. 18:377–385. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chen XM, Luan XY, Lei DP, Ma XJ, Liu XX, Liu J and Pan XL: Suppression of survivin expression by short hairpin RNA induces apoptosis in human laryngeal carcinoma cells. ORL J Otorhinolaryngol Relat Spec. 70:168–175. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Zhu H, Quan L, Zhou C, Bai J, Zhang G, Zhan Q and Xu N: Downregulation of survivin by RNAi inhibits the growth of esophageal carcinoma cells. Cancer Biol Ther. 4:974–978. 2005. View Article : Google Scholar : PubMed/NCBI |
